FY2028 Earnings Estimate for Panbela Therapeutics, Inc. (NASDAQ:PBLA) Issued By Roth Capital

Panbela Therapeutics, Inc. (NASDAQ:PBLAFree Report) – Equities researchers at Roth Capital issued their FY2028 earnings estimates for shares of Panbela Therapeutics in a research note issued on Monday, February 5th. Roth Capital analyst J. Aschoff expects that the company will post earnings of $9.34 per share for the year. The consensus estimate for Panbela Therapeutics’ current full-year earnings is ($194.60) per share.

Panbela Therapeutics (NASDAQ:PBLAGet Free Report) last posted its earnings results on Thursday, November 9th. The company reported ($53.80) earnings per share for the quarter, missing the consensus estimate of ($41.20) by ($12.60).

Separately, Roth Mkm reaffirmed a “buy” rating and set a $500.00 target price on shares of Panbela Therapeutics in a report on Monday, December 18th.

View Our Latest Report on Panbela Therapeutics

Panbela Therapeutics Price Performance

NASDAQ:PBLA opened at $1.16 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 0.21 and a quick ratio of 0.21. The firm has a market cap of $301,600.00, a price-to-earnings ratio of 0.00 and a beta of 1.58. The company has a 50 day moving average price of $11.29 and a 200-day moving average price of $19.75. Panbela Therapeutics has a 1-year low of $1.06 and a 1-year high of $936.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. HRT Financial LP acquired a new position in Panbela Therapeutics in the first quarter valued at about $30,000. Walleye Capital LLC purchased a new stake in Panbela Therapeutics during the second quarter worth about $217,000. Anson Funds Management LP purchased a new stake in Panbela Therapeutics during the first quarter worth about $72,000. UBS Group AG increased its stake in Panbela Therapeutics by 46,589.5% during the third quarter. UBS Group AG now owns 190,493 shares of the company’s stock worth $51,000 after purchasing an additional 190,085 shares during the period. Finally, Vanguard Group Inc. purchased a new stake in Panbela Therapeutics during the third quarter worth about $60,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Insider Buying and Selling

In other Panbela Therapeutics news, major shareholder Goldman Sachs Group Inc sold 3,643 shares of Panbela Therapeutics stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $14.20, for a total transaction of $51,730.60. Following the sale, the insider now owns 19,897 shares of the company’s stock, valued at approximately $282,537.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.11% of the stock is owned by insiders.

About Panbela Therapeutics

(Get Free Report)

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase.

See Also

Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.